Early trial results show promising outcomes for Roche’s new weight loss drug

Roche’s Promising Weight Loss Drug Shows Positive Results in Early-Stage Trial

Roche, a multinational healthcare company, has recently announced promising results from an early-stage trial of its experimental weight loss drug, CT-388. The drug, which is still in development, has shown significant potential in helping patients with obesity achieve substantial weight loss.

The Swiss company’s foray into the weight loss market began with its acquisition of Carmot Therapeutics for nearly $3 billion in December. With the introduction of CT-388, Roche aims to compete with other pharmaceutical giants such as Novo Nordisk and Eli Lilly in the rapidly growing obesity treatment sector.

In the phase one trial, patients who received CT-388 experienced an impressive weight loss of 18.8% compared to those who received a placebo. Additionally, all patients who were administered the drug lost more than 5% of their weight, with a significant percentage achieving weight loss of over 15% and 20%.

CT-388 works by mimicking the effects of two gut hormones – GLP-1 and GIP – to suppress appetite, similar to Eli Lilly’s Zepbound and Mounjaro. By targeting these hormones, Roche’s drug aims to achieve meaningful weight loss and regulate blood sugar levels with fewer side effects than existing treatments like Novo Nordisk’s Wegovy.

Roche noted that patients taking CT-388 did not experience any new or unexpected side effects, with mild to moderate gastrointestinal issues being the most common. The drug also showed promising results in normalizing blood sugar levels in a subgroup of patients with pre-diabetes.

Currently, Roche is conducting additional trials of CT-388 in patients with obesity and diabetes over a 12-week period. The company expects to release data from these trials in the second half of the year, offering further insights into the drug’s efficacy and safety profile.

With the weight loss drug market projected to reach $100 billion by the end of the decade, Roche’s CT-388 holds significant promise as a potential game-changer in the treatment of obesity and related conditions. Stay tuned for further updates on Roche’s innovative approach to tackling the global obesity epidemic.

Back To Top